LSI-201

LSI-201 is a lipid-based reformulation of the taxane chemotherapy agent docetaxel, developed by LipoSeuticals. As a microtubule stabilizer, docetaxel binds to the beta-subunit of tubulin, promoting the assembly of microtubules and inhibiting their depolymerization. This action leads to the stabilization of microtubules, which disrupts the normal dynamic reorganization of the microtubule network essential for vital interphase and mitotic cellular functions, ultimately resulting in cell cycle arrest at the G2/M phase and apoptosis. LSI-201 is administered intravenously and is intended for the treatment of various oncology indications, aiming to provide a more tolerable delivery system compared to conventional docetaxel formulations (such as Taxotere) that utilize surfactants like polysorbate 80, which are associated with hypersensitivity reactions.

Other names

docetaxel